Drug Development
Seattle Genetics initiates phase 1 trial of SGN-35 in Hodgkin, other hematologic malignancies
Published in Clinical Trials Week, December 18th, 2006
SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' proprietary technology to empower antibodies by linking them to potent cell-killing drugs.
Clay B. Siegall, PhD, president and chief executive officer of Seattle Genetics, said, "Many antibodies lack sufficient potency on their own to have a therapeutic benefit. ADCs exploit an antibody's ability to target tumor cells to deliver a highly potent drug payload, sparing nontargeted cells many of the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2006-12-18)
More Articles from Clinical Trials Week
- Dupuytren Contracture
Auxilium Pharmaceuticals initiates phase III trials for AA4500 in hand condition - Alcoholism Clinical Trial
Reports on alcoholism clinical trial findings from University of Pennsylvania, Department of Psychiatry provide new insights - Angiogenesis
Studies from University of Pennsylvania yield new data on angiogenesis - Arthritis Clinical Trial
Researchers from Vanderbilt University describe findings in arthritis clinical trial - Breast Cancer Quality of Care
New breast cancer quality of care study findings have been reported from Stanford University - Breast Cancer Quality of Care
New findings from Fred Hutchinson Cancer Research Center describe advances in breast cancer quality of care - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
